2016 Q1 Form 10-K Financial Statement
#000119312516505167 Filed on March 15, 2016
Income Statement
Concept | 2016 Q1 | 2014 Q4 | 2014 Q3 |
---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $2.690M | $1.600M | $1.220M |
YoY Change | 38.66% | 150.0% | 177.27% |
% of Gross Profit | |||
Research & Development | $3.546M | $2.380M | $2.886M |
YoY Change | 50.94% | 14.98% | 2.91% |
% of Gross Profit | |||
Depreciation & Amortization | $13.20K | $10.00K | $7.235K |
YoY Change | 61.98% | 26.77% | |
% of Gross Profit | |||
Operating Expenses | $6.238M | $3.980M | $4.109M |
YoY Change | 45.33% | 46.86% | 26.6% |
Operating Profit | -$6.238M | -$3.984M | -$4.109M |
YoY Change | 45.33% | 47.17% | 26.6% |
Interest Expense | $730.0K | $470.0K | -$910.0K |
YoY Change | -161.86% | -64.66% | -66.04% |
% of Operating Profit | |||
Other Income/Expense, Net | $117.9K | $20.00K | $5.924K |
YoY Change | 90.43% | 0.0% | -40.76% |
Pretax Income | -$5.386M | -$3.490M | -$5.010M |
YoY Change | -0.44% | 158.52% | -15.26% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$5.386M | -$3.490M | -$5.010M |
YoY Change | -0.44% | 157.63% | -15.26% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$65.05K | -$50.62K | -$74.59K |
COMMON SHARES | |||
Basic Shares Outstanding | 82.88M shares | 69.12M shares | 67.17M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2016 Q1 | 2014 Q4 | 2014 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $52.50M | $39.30M | $41.40M |
YoY Change | -26.57% | 65.82% | 49.46% |
Cash & Equivalents | $22.23M | $9.097M | $11.26M |
Short-Term Investments | $30.20M | $30.20M | $30.20M |
Other Short-Term Assets | $1.000M | $4.600M | $4.300M |
YoY Change | -77.27% | 187.5% | 330.0% |
Inventory | |||
Prepaid Expenses | |||
Receivables | |||
Other Receivables | |||
Total Short-Term Assets | $53.48M | $43.83M | $45.76M |
YoY Change | -29.61% | 73.1% | 59.79% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $178.4K | $71.38K | $71.28K |
YoY Change | 150.71% | 75.68% | 53.84% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Total Long-Term Assets | $187.2K | $80.27K | $80.17K |
YoY Change | 133.97% | 62.1% | 45.17% |
TOTAL ASSETS | |||
Total Short-Term Assets | $53.48M | $43.83M | $45.76M |
Total Long-Term Assets | $187.2K | $80.27K | $80.17K |
Total Assets | $53.67M | $43.91M | $45.84M |
YoY Change | -29.43% | 73.07% | 59.76% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $1.251M | $1.814M | $524.8K |
YoY Change | 19.13% | 113.24% | -64.38% |
Accrued Expenses | $1.412M | $4.041M | $5.414M |
YoY Change | -70.58% | 213.53% | 251.96% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.664M | $5.855M | $5.939M |
YoY Change | -54.46% | 173.65% | 97.2% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $500.0K | $2.800M | $3.300M |
YoY Change | -86.11% | 55.56% | -8.33% |
Total Long-Term Liabilities | $500.0K | $2.800M | $3.300M |
YoY Change | -86.11% | 55.56% | -8.33% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.664M | $5.855M | $5.939M |
Total Long-Term Liabilities | $500.0K | $2.800M | $3.300M |
Total Liabilities | $3.129M | $8.666M | $9.222M |
YoY Change | -66.81% | 117.83% | 40.24% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$95.46M | -$69.84M | -$66.35M |
YoY Change | 26.85% | 28.54% | 25.24% |
Common Stock | $82.87K | $69.12K | $67.17K |
YoY Change | 1.05% | 27.68% | 24.42% |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $50.54M | $35.24M | $36.62M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $53.67M | $43.91M | $45.84M |
YoY Change | -29.43% | 73.07% | 59.76% |
Cashflow Statement
Concept | 2016 Q1 | 2014 Q4 | 2014 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$5.386M | -$3.490M | -$5.010M |
YoY Change | -0.44% | 157.63% | -15.26% |
Depreciation, Depletion And Amortization | $13.20K | $10.00K | $7.235K |
YoY Change | 61.98% | 26.77% | |
Cash From Operating Activities | -$5.930M | -$3.980M | -$3.550M |
YoY Change | 56.46% | -3.63% | 110.06% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | -$20.00K | -$10.00K |
YoY Change | -100.0% | ||
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$70.00K | $10.00K | $30.00K |
YoY Change | 75.0% | -100.15% | -100.71% |
Cash From Investing Activities | -$70.00K | -$10.00K | $20.00K |
YoY Change | 75.0% | -99.85% | -100.48% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | -10.00K | 1.820M | 0.000 |
YoY Change | -100.03% | 857.89% | -100.0% |
NET CHANGE | |||
Cash From Operating Activities | -5.930M | -3.980M | -3.550M |
Cash From Investing Activities | -70.00K | -10.00K | 20.00K |
Cash From Financing Activities | -10.00K | 1.820M | 0.000 |
Net Change In Cash | -6.010M | -2.170M | -3.530M |
YoY Change | -118.65% | -79.81% | -129.22% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$5.930M | -$3.980M | -$3.550M |
Capital Expenditures | $0.00 | -$20.00K | -$10.00K |
Free Cash Flow | -$5.930M | -$3.960M | -$3.540M |
YoY Change | 56.14% | -4.12% | 109.47% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2016Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
82880360 | shares |
CY2015Q2 | dei |
Entity Public Float
EntityPublicFloat
|
316734842 | |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
14622115 | |
CY2012Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
498587 | |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1409939 | |
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
21391252 | |
CY2013Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1819562 | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
2215958 | |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3884610 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2014Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
1.50 | |
CY2014Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
69119092 | shares |
CY2014Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2014Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2014Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
69119092 | shares |
CY2014Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2014Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
15839 | |
CY2014Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
11801 | |
CY2014Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
31956 | |
CY2014Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
35242330 | |
CY2014Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
|
15839 | |
CY2014Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
43973 | |
CY2014Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
105015871 | |
CY2014Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
4158 | |
CY2014Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
4040816 | |
CY2014Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
19997 | |
CY2014Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1814210 | |
CY2014Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
2794891 | |
CY2014Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
4040816 | |
CY2014Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-69842660 | |
CY2014Q4 | us-gaap |
Liabilities
Liabilities
|
8665756 | |
CY2014Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
43908086 | |
CY2014Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
69119 | |
CY2014Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2014Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
|
4056655 | |
CY2014Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
113193 | |
CY2014Q4 | us-gaap |
Litigation Reserve Current
LitigationReserveCurrent
|
3500000 | |
CY2014Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
5855026 | |
CY2014Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2014Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
2794891 | |
CY2014Q4 | us-gaap |
Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
|
3715383 | |
CY2014Q4 | us-gaap |
Assets
Assets
|
43908086 | |
CY2014Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
71377 | |
CY2014Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
CY2014Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
24895000 | |
CY2014Q4 | us-gaap |
Assets Current
AssetsCurrent
|
43827821 | |
CY2015Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
82850619 | shares |
CY2015Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
|
2.23 | |
CY2015Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
|
4250000 | shares |
CY2015Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
2036663 | shares |
CY2015Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
CY2015Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2015Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
82850619 | shares |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
1.38 | |
CY2014Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
30315 | |
CY2014Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
10870 | |
CY2014Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
385496 | |
CY2014Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
4552698 | |
CY2014Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
9096778 | |
CY2014Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
184570 | |
CY2014Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26462962 | |
CY2014Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26462962 | |
CY2014Q4 | us-gaap |
Loss Contingency Receivable
LossContingencyReceivable
|
3500000 | |
CY2014Q4 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
115000 | |
CY2014Q4 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
571428 | |
CY2014Q4 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
30495 | |
CY2014Q4 | cprx |
Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
|
15839 | |
CY2014Q4 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
333928 | |
CY2014Q4 | cprx |
Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
|
3715383 | |
CY2014Q4 | cprx |
Prepaid Offering Costs
PrepaidOfferingCosts
|
20029 | |
CY2014Q4 | cprx |
Net Operating Loss Carryforward And Start Up Costs
NetOperatingLossCarryforwardAndStartUpCosts
|
22898000 | |
CY2014Q4 | cprx |
Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
|
4065 | |
CY2015Q4 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
|
2036663 | shares |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
4250000 | shares |
CY2015Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
150000000 | shares |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
2.23 | |
CY2015Q4 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
|
1.38 | |
CY2015Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2015Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
207421 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
185244 | |
CY2015Q4 | us-gaap |
Accrued Rent Noncurrent
AccruedRentNoncurrent
|
176293 | |
CY2015Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
17642 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
1506495 | |
CY2015Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
894846 | |
CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
55476311 | |
CY2015Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
8888 | |
CY2015Q4 | us-gaap |
Deferred Tax Assets Net
DeferredTaxAssetsNet
|
34309000 | |
CY2015Q4 | us-gaap |
Assets Current
AssetsCurrent
|
59901133 | |
CY2015Q4 | us-gaap |
Operating Loss Carryforwards
OperatingLossCarryforwards
|
49922000 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
226655 | |
CY2015Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
|
176293 | |
CY2015Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
330490 | |
CY2015Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
145469078 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
18093 | |
CY2015Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
1646476 | |
CY2015Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
194386 | |
CY2015Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
1794127 | |
CY2015Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
|
1008363 | |
CY2015Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
1646476 | |
CY2015Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-90075618 | |
CY2015Q4 | us-gaap |
Liabilities
Liabilities
|
4625259 | |
CY2015Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
60101570 | |
CY2015Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
82851 | |
CY2015Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2015Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current And Noncurrent
AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
|
1822769 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
220053 | |
CY2015Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
70074 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
|
453478 | |
CY2015Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3440603 | |
CY2015Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
CY2015Q4 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
1008363 | |
CY2015Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
213644 | |
CY2015Q4 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
2517634 | |
CY2015Q4 | us-gaap |
Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
|
3717229 | |
CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
2589800 | |
CY2015Q4 | us-gaap |
Assets
Assets
|
60101570 | |
CY2015Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
191549 | |
CY2015Q4 | us-gaap |
Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
|
34716 | |
CY2015Q4 | us-gaap |
Prepaid Rent
PrepaidRent
|
1252 | |
CY2015Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
436726 | |
CY2015Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
1504738 | |
CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
28235016 | |
CY2015Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
261623 | |
CY2015Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
26444150 | |
CY2015Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
26444150 | |
CY2015Q4 | cprx |
Accrued License Fees Current
AccruedLicenseFeesCurrent
|
52500 | |
CY2015Q4 | cprx |
Prepaid Research Fee
PrepaidResearchFee
|
915194 | |
CY2015Q4 | cprx |
Prepaid Subscription Fees
PrepaidSubscriptionFees
|
26602 | |
CY2015Q4 | cprx |
Accrued Liabilities Noncurrent
AccruedLiabilitiesNoncurrent
|
176293 | |
CY2013 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
3796000 | |
CY2013 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
4652684 | |
CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
175855 | |
CY2015Q4 | cprx |
Accrued Non Clinical And Clinical Trial Expenses
AccruedNonClinicalAndClinicalTrialExpenses
|
332905 | |
CY2015Q4 | cprx |
Certificates Of Deposit Fair Value Disclosure
CertificatesOfDepositFairValueDisclosure
|
3717229 | |
CY2015Q4 | cprx |
Net Operating Loss Carryforward And Start Up Costs
NetOperatingLossCarryforwardAndStartUpCosts
|
28682000 | |
CY2015Q4 | cprx |
Prepaid Precommercial Expenses
PrepaidPrecommercialExpenses
|
90248 | |
CY2013Q4 | us-gaap |
Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
|
3 | Lawsuits |
CY2015Q1 | us-gaap |
Payments For Tenant Improvements
PaymentsForTenantImprovements
|
131000 | |
CY2015Q1 | cprx |
Area Of Leased Property
AreaOfLeasedProperty
|
5200 | sqft |
CY2015Q1 | cprx |
Lease Expiration Year
LeaseExpirationYear
|
2022 | |
CY2015Q1 | cprx |
Lease Termination Rights Exercise Date
LeaseTerminationRightsExerciseDate
|
2017-11 | |
CY2013 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-9875674 | |
CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P3Y | |
CY2013 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
6.00 | |
CY2013 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.27 | |
CY2013 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
8277526 | shares |
CY2013 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.37 | pure |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0045 | pure |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
0.48 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0053 | pure |
CY2013 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
45452447 | shares |
CY2013 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
9432 | |
CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12154596 | |
CY2013 | us-gaap |
Revenues
Revenues
|
0 | |
CY2013 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
14095194 | |
CY2013 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
299972 | |
CY2013 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
166633 | |
CY2013 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-10311658 | |
CY2013 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
47421 | |
CY2013 | us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
9978618 | |
CY2013 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-12154596 | |
CY2013 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
CY2013 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2013 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
175855 | |
CY2013 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
30000 | |
CY2013 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1890359 | |
CY2013 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
69930 | |
CY2013 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
806019 | |
CY2013 | us-gaap |
Operating Expenses
OperatingExpenses
|
10311658 | |
CY2013 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
569384 | |
CY2013 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
569384 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
17975 | |
CY2013 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-514874 | |
CY2013 | us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
2491249 | |
CY2013 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
14071694 | |
CY2013 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-7496801 | |
CY2013 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
18178494 | |
CY2013 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
4083300 | |
CY2013 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
8096774 | |
CY2013 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
23500 | |
CY2013 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1005071 | |
CY2013 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2214884 | |
CY2013 | us-gaap |
Depreciation
Depreciation
|
22483 | |
CY2013 | cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
3862250 | shares |
CY2013 | cprx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0.00 | pure |
CY2014 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-12941783 | |
CY2014 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
3.12 | |
CY2014 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.24 | |
CY2014 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
7550534 | shares |
CY2014 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | |
CY2014 | us-gaap |
Loss Contingency Claims Dismissed Number
LossContingencyClaimsDismissedNumber
|
2 | Lawsuits |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.15 | pure |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
CY2014 | us-gaap |
Loss Contingency Date Of Dismissal
LossContingencyDateOfDismissal
|
2014-01-03 | |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0118 | pure |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.41 | |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0203 | pure |
CY2014 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
64142534 | shares |
CY2014 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
57323 | |
CY2014 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-15509061 | |
CY2014 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
522000 | |
CY2014 | us-gaap |
Revenues
Revenues
|
0 | |
CY2014 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
26725130 | |
CY2014 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2943256 | |
CY2014 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
409476 | |
CY2014 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14591428 | |
CY2014 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
76233 | |
CY2014 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
5508000 | |
CY2014 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
1335040 | |
CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
767838 | |
CY2014 | us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
8979900 | |
CY2014 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-15509061 | |
CY2014 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
10131 | |
CY2014 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
CY2014 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2014 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
777969 | |
CY2014 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
44000 | |
CY2014 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
993866 | |
CY2014 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
90163 | |
CY2014 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
6880820 | |
CY2014 | us-gaap |
Operating Expenses
OperatingExpenses
|
14591428 | |
CY2014 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-8741030 | |
CY2014 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
28563633 | |
CY2014 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1316503 | |
CY2014 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
18537 | |
CY2014 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
1339100 | |
CY2014 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
963421 | |
CY2014 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
26725130 | |
CY2014 | us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
296193 | |
CY2014 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10117774 | |
CY2014 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
522000 | |
CY2014 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
2748704 | |
CY2014 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4473654 | |
CY2014 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
18537 | |
CY2014 | us-gaap |
Depreciation
Depreciation
|
26574 | |
CY2014 | cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
1262296 | shares |
CY2014 | cprx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0.00 | pure |
CY2014 | cprx |
Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
|
1.00 | pure |
CY2015 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2015 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: 'Times New Roman'; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; WORD-SPACING: 0px; WIDOWS: 1; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>Organization and Description of Business</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Catalyst Pharmaceuticals, Inc., formerly known as Catalyst Pharmaceutical Partners, Inc., (the “Company”), is a development-stage biopharmaceutical company focused on developing and commercializing innovating therapies for people with rare debilitating diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), infantile spasms and Tourette’s Disorder. The Company was incorporated in Delaware in July 2006. It is the successor by merger to Catalyst Pharmaceutical Partners, Inc., a Florida corporation, which commenced operations in January 2002.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through December 31, 2015. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 11.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Capital Resources</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> On January 31, 2014, the Company filed a Shelf Registration Statement on Form S-3 (the 2014 Shelf Registration Statement) with the U.S. Securities and Exchange Commission (SEC) to sell up to $100 million of common stock. This registration statement (file No. 333-193699) was declared effective by the SEC on March 19, 2014. The Company has conducted two registered direct offerings under the 2014 Shelf Registration Statement. (See Note 11).</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> While there can be no assurance, based on currently available information, the Company estimates that it currently has sufficient working capital to support its operations through the first quarter of 2017. The Company will require additional capital to support its operations in periods after the first quarter of 2017.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> The Company may raise required funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any such required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business.</p> <br class="Apple-interchange-newline" /> </div> | |
CY2015 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-18015221 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | shares |
CY2015 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
|
4.64 | |
CY2015 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | |
CY2015 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
145002 | shares |
CY2015 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
|
P2Y11M5D | |
CY2015 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.25 | |
CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P2Y11M5D | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.30 | |
CY2015 | us-gaap |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
|
0.47 | |
CY2015 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
6710997 | shares |
CY2015 | dei |
Document Type
DocumentType
|
10-K | |
CY2015 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001369568 | |
CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P4Y9M | |
CY2015 | dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | |
CY2015 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.35 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
CY2015 | us-gaap |
Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
|
P4Y9M | |
CY2015 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>m.</b></td> <td valign="top" align="left"><b>CONCENTRATION OF CREDIT RISK.</b> The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e. money market funds), short-term investments and certificates of deposit. The Company places its cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts.</td> </tr> </table> </div> | |
CY2015 | us-gaap |
Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
|
0.04 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
1.02 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.00 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
3.02 | |
CY2015 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2015 | dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | |
CY2015 | dei |
Entity Registrant Name
EntityRegistrantName
|
CATALYST PHARMACEUTICALS, INC. | |
CY2015 | dei |
Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
|
No | |
CY2015 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2015-12-31 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0213 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
1760000 | shares |
CY2015 | dei |
Entity Voluntary Filers
EntityVoluntaryFilers
|
No | |
CY2015 | us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>r.</b></td> <td valign="top" align="left"><b>RECLASSIFICATIONS.</b> Certain prior year amounts in the financial statements have been reclassified to conform to the current year presentation.</td> </tr> </table> </div> | |
CY2015 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.95 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0100 | pure |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
2.13 | |
CY2015 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <table> <tr> <td valign="top" width="4%" align="left"><b>a.</b></td> <td valign="top" align="left"><b>USE OF ESTIMATES.</b> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</td> </tr> </table> </div> | |
CY2015 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
1249608 | shares |
CY2015 | us-gaap |
Loss Contingency Actions Taken By Court Arbitrator Or Mediator
LossContingencyActionsTakenByCourtArbitratorOrMediator
|
20 days | |
CY2015 | us-gaap |
Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
|
0.15 | pure |
CY2015 | dei |
Trading Symbol
TradingSymbol
|
CPRX | |
CY2015 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
80858393 | shares |
CY2015 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0.00 | pure |
CY2015 | us-gaap |
Loss Contingency Settlement Agreement Date
LossContingencySettlementAgreementDate
|
April 16, 2015 | |
CY2015 | us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | Segment |
CY2015 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
23465 | |
CY2015 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-20232958 | |
CY2015 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
390351 | |
CY2015 | us-gaap |
Revenues
Revenues
|
0 | |
CY2015 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
34873869 | |
CY2015 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
452040 | |
CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
|
1307895 | |
CY2015 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20398352 | |
CY2015 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
100389 | |
CY2015 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
9414000 | |
CY2015 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
3617261 | |
CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
|
1510018 | |
CY2015 | us-gaap |
Payments For Proceeds From Short Term Investments
PaymentsForProceedsFromShortTermInvestments
|
-18812 | |
CY2015 | us-gaap |
Litigation Settlement Amount
LitigationSettlementAmount
|
-3500000 | |
CY2015 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-20232958 | |
CY2015 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
|
75440 | |
CY2015 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
0 | |
CY2015 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | |
CY2015 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1585458 | |
CY2015 | us-gaap |
Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
|
69000 | |
CY2015 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-65005 | |
CY2015 | us-gaap |
Lease And Rental Expense
LeaseAndRentalExpense
|
129727 | |
CY2015 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
19138238 | |
CY2015 | us-gaap |
Operating Expenses
OperatingExpenses
|
20398352 | |
CY2015 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-6499 | |
CY2015 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
37159958 | |
CY2015 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1895738 | |
CY2015 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11801342 | |
CY2015 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
390351 | |
CY2015 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
1134939 | |
CY2015 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8597010 | |
CY2015 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
|
1721523 | |
CY2015 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
1721523 | |
CY2015 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
3311599 | |
CY2015 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-20083 | |
CY2015 | us-gaap |
Proceeds From Payments For In Interest Bearing Deposits In Banks
ProceedsFromPaymentsForInInterestBearingDepositsInBanks
|
-1846 | |
CY2015 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
34873869 | |
CY2015 | us-gaap |
Depreciation
Depreciation
|
34468 | |
CY2015 | cprx |
Shares Issued During Period Warrants Exercised
SharesIssuedDuringPeriodWarrantsExercised
|
1178261 | shares |
CY2015 | cprx |
Maximum Maturity Period Of Cash And Cash Equivalent
MaximumMaturityPeriodOfCashAndCashEquivalent
|
Three months | |
CY2015 | cprx |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
|
0.00 | pure |
CY2015 | cprx |
Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
|
1.00 | pure |
CY2015 | cprx |
Non Cash Incentive Received From Lessor
NonCashIncentiveReceivedFromLessor
|
131175 | |
CY2015 | cprx |
Operating Losses Carryforwards Expiration Dates
OperatingLossesCarryforwardsExpirationDates
|
Beginning in 2023 and ending in 2035 | |
CY2013Q4 | us-gaap |
Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
|
3 | Lawsuits |
CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.07 | |
CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3811119 | |
CY2014Q1 | us-gaap |
Revenues
Revenues
|
0 | |
CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3508365 | |
CY2014Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
335514 | |
CY2015Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.07 | |
CY2015Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5410259 | |
CY2015Q1 | us-gaap |
Revenues
Revenues
|
0 | |
CY2015Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4291915 | |
CY2015Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
1180278 | |
CY2014Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
CY2014Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3198020 | |
CY2014Q2 | us-gaap |
Revenues
Revenues
|
0 | |
CY2014Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-2990173 | |
CY2014Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
223591 | |
CY2015Q2 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
CY2015Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4558503 | |
CY2015Q2 | us-gaap |
Revenues
Revenues
|
0 | |
CY2015Q2 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4897330 | |
CY2015Q2 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-333956 | |
CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.07 | |
CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5009892 | |
CY2014Q3 | us-gaap |
Revenues
Revenues
|
0 | |
CY2014Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-4109029 | |
CY2014Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
906787 | |
CY2015Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
CY2015Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4449038 | |
CY2015Q3 | us-gaap |
Revenues
Revenues
|
0 | |
CY2015Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-5017428 | |
CY2015Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-521731 | |
CY2014Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.05 | |
CY2014Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-3490030 | |
CY2014Q4 | us-gaap |
Revenues
Revenues
|
0 | |
CY2014Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-3983861 | |
CY2014Q4 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-472026 | |
CY2015Q4 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.07 | |
CY2015Q4 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5815158 | |
CY2015Q4 | us-gaap |
Revenues
Revenues
|
0 | |
CY2015Q4 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6191679 | |
CY2015Q4 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-389596 |